Please use this identifier to cite or link to this item: 10.1093/europace/euz216
Title: Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry
Authors: ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators Group
Balabanski, Tosho
Brugada, Josep
Kalejs, Oskars
Keywords: Ablation;Atrial fibrillation;EHRA registry;Recurrence;Rhythm monitoring;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Cardiology and Cardiovascular Medicine;Physiology (medical)
Issue Date: 1-Dec-2019
Citation: ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators Group , Balabanski , T , Brugada , J & Kalejs , O 2019 , ' Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry ' , Europace , vol. 21 , no. 12 , pp. 1802-1808 . https://doi.org/10.1093/europace/euz216
Abstract: Aims: Monitoring of patients after ablation had wide variations in the ESC-EHRA atrial fibrillation ablation long-term (AFA-LT) registry. We aimed to compare four different monitoring strategies after catheter AF ablation. Methods and results: The ESC-EHRA AFA-LT registry included 3593 patients who underwent ablation. Arrhythmia monitoring during follow-up was performed by 12-lead electrocardiogram (ECG), Holter ECG, trans-telephonic ECG monitoring (TTMON), or an implanted cardiac monitoring (ICM) system. Patients were selected to a given monitoring group according to the most extensive ECG tool used in each of them. Comparison of the probability of freedom from recurrences was performed by censored log-rank test and presented by Kaplan-Meier curves. The rhythm monitoring methods were used among 2658 patients: ECG (N = 578), Holter ECG (N = 1874), TTMON (N = 101), and ICM (N = 105). A total of 767 of 2658 patients (28.9%) had AF recurrences during follow-up. Censored log-rank test discovered a lower probability of freedom from relapses, which was detected with ICM compared to TTMON, ECG, and Holter ECG (P < 0.001). The rate of freedom from AF recurrences was 50.5% among patients using the ICM while it was 65.4%, 70.6%, and 72.8% using the TTMON, ECG, and Holter ECG, respectively. Conclusion: Comparing all main electrocardiographic monitoring methods in a large patient sample, our results suggest that post-ablation recurrences of AF are significantly underreported by TTMON, ECG, and Holter ECG. The ICM estimates AF ablation recurrences most reliably and should be a preferred mode of monitoring for trials evaluating novel AF ablation techniques.
Description: Funding Information: Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011-21), Amgen Cardiovascular (2009-18), AstraZeneca (2014-21), Bayer AG (2009-18), Boehringer Ingelheim (2009-19), Boston Scientific (2009-12), The Bristol Myers Squibb and Pfizer Alliance (2011-19), Daiichi Sankyo Europe GmbH (2011-20), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014-17), Edwards (2016-19), Gedeon Richter Plc. (2014-16), Menarini Int. Op. (2009-12), MSD-Merck & Co. (2011-14), Novartis Pharma AG (2014-20), ResMed (2014-16), Sanofi (2009-11), Servier (2009-21), and Vifor (2019-22). Funding Information: Conflict of interest: T.B. has received grants from St. Jude Medical (Abbott), Biotronik, and Medtronic; speaker honoraria from Actavis-TEVA, Berlin-Chemie, Merck, Sanofi-Aventis, and Servier; and has served as a consultant for Boehringer Ingelheim. A.P.M. has no conflicts to disclose with respect to the present manuscript. Outside the present work, he received honoraria for participation in study committees sponsored by Bayer, Novartis, and Fresenius. J.K. has received speaker honoraria from Bayer, Boehringer Ingelheim, Biosense Webster, Biotronik, Boston Scientific, Medtronic, Merck Sharp & Dohme, Pfizer, and St. Jude Medical (Abbott); and has served as a consultant for Bayer, Boehringer Ingelheim, Biosense Webster, Boston Scientific, Etix, Medtronic, Merck Sharp & Dohme, Liva Nova (MicroPort), and St. Jude Medical (Abbott). L.T. is a trial committee member for Servier and CVIE Therapeutics and speakers bureau member for Servier. N.D. reports research grants from Abbott, Biotronik, Boston Scientific, and Medtronic to the institution without personal financial benefits. And all other authors have no conflict of interest to declare. Publisher Copyright: © 2019 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019.
DOI: 10.1093/europace/euz216
ISSN: 1099-5129
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.